Abstract Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of
cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in …

Due to the key role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of
immunoinflammatory diseases, TNF-α inhibitors have been successfully developed and …

Objective There are numerous biological therapies and small molecules licensed for luminal
Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning …

Background & Aims We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an
oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative …

Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …

Non‐invasive localization of lesions and specific targeted therapy are still the main
challenges for inflammatory bowel disease (IBD). Ta, as a medical metal element, has been …

Background & Aims Early Crohn's disease (CD) treatment involves anti-tumor necrosis factor
(TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment …

METHODS: This was a pooled analysis of patient-level data from 299 patients with CD from
4 clinical trials. Proportions of patients treated with each biologic were compared for …

Abstract Background Surgical management in Ulcerative Colitis (UC) is typically utilised in
medically refractory cases and, therefore, it is a useful marker for efficacy of medical …

Increasing insights into the immunopathogenesis of inflammatory bowel diseases [IBD] have
led to the advent of targeted therapies that inhibit crucial mediators of the inflammatory …